Business context and reporting period
Issuer mismatch: The supplied filing is for AFH Acquisition X, Inc., not Bone Biologics Corp. It is a Form 10-Q for the quarter ended April 30, 2014, and describes AFH as a development-stage blank-check company seeking an acquisition or merger. It reports no active operations and says it was not negotiating with a target. The filing does not establish that it relates to Bone Biologics.
Financial results and liquidity
- Revenue: $0 for the three and six months ended April 30, 2014, and since inception.
- Net loss: $1,785 for the quarter and $3,764 for the six months, versus $1,473 and $3,091, respectively, in the comparable 2013 periods. Six-month expenses before franchise tax were $3,364, compared with $2,691 in 2013.
- Cash flow: Six-month operating cash use was $2,894, versus $460 in 2013. Financing provided $2,572, entirely from parent advances; cash declined $322 to $58.
- Balance sheet at April 30, 2014: Cash and total assets were $58; current liabilities were $43,627, comprising $4,454 accrued expenses and $39,173 due to parent. Working capital was negative $43,569; stockholders’ deficit was also $43,569. The parent advances have no repayment terms stated.
- Debt, margins and shares: No separate interest-bearing debt, gross margin or operating margin is reported. There was no revenue from which to calculate margins. The company reported 5,000,000 common shares outstanding; weighted average shares were 5,000,000.
Material changes versus comparable periods
Quarterly and six-month losses increased from 2013, while six-month operating cash use also rose. Cash fell from $380 at October 31, 2013, to $58 at April 30, 2014. Parent advances increased by $2,572 over the six months; accrued expenses rose by $870. The accumulated deficit reached $68,569.
Outlook, risks and unusual items
Management says continued existence depends on raising capital or acquiring a marketable company. It states there is substantial doubt about the company’s ability to continue as a going concern, citing recurring losses, negative working capital and limited cash. No assurance is given that it can find a target or obtain equity funding. A business combination could materially dilute existing shareholders; the filing also notes potential market-price pressure if securities are issued and later sold. No financial guidance is provided. The filing reports no legal proceedings or material off-balance-sheet arrangements.
Important facts to verify
- Confirm issuer identity: the filing names AFH Acquisition X, Inc., not Bone Biologics Corp.
- Confirm the intended reporting period: the filing’s quarter ended April 30, 2014, which may not match the metadata’s “2014 Q1.”
- Verify parent advances and funding arrangements, including the absence of stated repayment terms.
- Assess the going-concern warning, access to additional capital, and prospects for a business combination.